Lung Cancer

Joint tumor board pushes for more success and survival in lung cancer [Video]

PHILADELPHIA (WPVI) — Collaboration is an essential for advancing medicine.

Temple Health and Fox Chase Cancer Center recently began a collaboration aimed at pushing the survival envelope in lung cancer.

“Even in the metastatic setting, we are able to cure a few of our patients. But I think the percentages are way too low. And that’s unacceptable,” says Dr. Hossein Borghaei, chair of thoracic medical oncology at Fox Chase Cancer Center.

In his time at Fox Chase Cancer Center, Dr. Borghaei has seen many new drugs extend the lives for lung cancer patients.

And at the Temple Lung Center, Dr. Joseph Friedberg, chair of thoracic surgery, is developing new surgical techniques.

“Every patient is different, and it’s always a bit of a puzzle,” says Dr. Friedberg.

Now the two hospitals are using a new tactic – a joint tumor board – to advance lung cancer treatment.

Tumor boards are groups of doctors and other specialists who meet regularly.

“They all …

Watch/Read More
Lung Cancer

SPOTLIGHT: zolbetuximab and m-FOLFOX6 in CLDN18.2+, HER2- GEJ cancer [Video]

Kohei Shitara, MD, National Cancer Center Hospital East, Chiba, Japan, provides an overview of findings from the Phase III SPOTLIGHT trial (NCT03504397), which assessed zolbetuximab in patients with CLDN18.2-positive, HER2-negative, locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Zolbetuximab is a first-in-class monoclonal antibody targeting CLDN18.2, and patients were given modified-FOLFOX6 with or without zolbetuximab. 2735 patients were recruited, and addition of zolbetuximab significantly improved progression-free survival and overall survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.